Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 11/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.40 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3674260 | 0.82 | SIGMAR1 (0.47) | HRH3SIGMAR1CHRM2CHRM4CHRM5 | |
| SCHEMBL3670401 | 0.80 | HRH3 (0.48) | HRH3SIGMAR1 | |
| SCHEMBL12304468 | 0.79 | HRH3 (0.47) | HRH3SIGMAR1 | |
| SCHEMBL26275998 | 0.77 | HRH3 (0.49) | HRH3SIGMAR1 | |
| SCHEMBL7006254 | 0.76 | CHRM2 (0.53) | HRH3SIGMAR1CHRM2CHRM4CHRM5 | |
| SCHEMBL791907 | 0.74 | CHRM2 (0.51) | HRH3SIGMAR1CHRM2CHRM4CHRM5 | |
| SCHEMBL22281963 | 0.73 | HRH3 (0.47) | HRH3SIGMAR1 | |
| SCHEMBL7004839 | 0.73 | SIGMAR1 (0.52) | HRH3SIGMAR1 | |
| SCHEMBL7004397 | 0.72 | SIGMAR1 (0.43) | HRH3SIGMAR1 | |
| SCHEMBL19112496 | 0.72 | CHRM2 (0.45) | SIGMAR1CHRM2CHRM4CHRM5CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11718628-B2 | SREBP inhibitors comprising a 6-membered central ring | CAPULUS THERAPEUTICS, LLC (US) | 2023-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11718628-B2 | SREBP inhibitors comprising a 6-membered central ring | SREBF1, SREBF2, XBP1 | HRH3 4786/4885SIGMAR1 1199/4885CHRM2 4858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.